Xeris Pharmaceuticals' glucagon therapy Gvoke, a treatment for hypoglycemia in patients with diabetes, has gained FDA approval. The pre-filled glucagon pen can be used in patients with diabetes ages 2 and older.
FDA approves Xeris' treatment for hypoglycemia in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.